IGF-1 LR3, however, can be administered exogenously to bypass this indirect process and produce faster results
The World Anti-Doping Agency (WADA) lists IGF-1 and its analogs, including IGF-1 LR3, as prohibited substances
Regulatory Status Always follow national, regional, or institutional regulations when purchasing, storing, and using this compound
At minimum: IGF-1 every 4 weeks, fasting glucose and insulin every 2 weeks initially (monthly once stable), HbA1c every 6 weeks, liver enzymes monthly, and comprehensive metabolic panel quarterly
The blend is supplied as a white lyophilized powder, water-soluble, and should be stored refrigerated at 28 C